stock options


Treasury yields inched higher Friday, but ended lower on the week as a combination of concerns about geopolitics and uncertainty about President Donald Trumps policy priorities helped to support buying in the perceived safety of government bonds.

On Friday, yields mostly ticked up for a second straight session as the so-called reflation trade was rekindled amid Trumps promise to reveal details about fiscal stimulus, including tax cuts. The prospect of deregulation, lower taxes and other fiscal stimulusthe centerpieces of Trumps campaignwas one of the central reasons yields climbed following the Nov. 8 election, with the 10-year yield climbing to 2.6% in mid-December from 1.867% Election Day.

stock options: CSI Compressco LP(CCLP)


Advisors’ Opinion:

  • [By Lisa Levin]

    CSI Compressco LP (NYSE: CCLP) shares dropped 15 percent to $7.90. CSI Compressco lowered its quarterly cash distribution to $0.1875 per outstanding common unit. CSI Compressco is expected to release its Q1 earnings results on Tuesday, May 9, 2017.

stock options: Hercules Offshore Inc.(HERO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Hercules Offshore, Inc. (NASDAQ: HERO) shares dropped 46 percent to $1.05 as the company reported that it has entered into a restructuring support agreement with lenders.

  • [By Monica Gerson]

    Hercules Offshore, Inc. (NASDAQ: HERO) is estimated to post a quarterly loss at $1.79 per share on revenue of $68.65 million.

    You On Demand Holdings, Inc. (NASDAQ: YOD) is expected to report its quarterly earnings.

stock options: Cerulean Pharma Inc.(CERU)


Advisors’ Opinion:

  • [By Lisa Levin]

    Cerulean Pharma Inc (NASDAQ: CERU) shares dropped 62 percent to $1.27. Cerulean Pharma and Dar茅 Bioscience reported that they have entered into a stock purchase agreement. Cerulean also announced plans to reduce workforce by 11 people. The company reported that it has sold CRLX101 and CRLX301 to BlueLink Pharmaceuticals for $1.5 million and also agreed to sell Dynamic Tumor Targeting Platform to Novartis for $6 million.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha) Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha) Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period. Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share. Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement. Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share. Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76. QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share. Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering. Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update. Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million. The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62. Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold. Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split. Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period. AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016. Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli

stock options: MPLX LP(MPLX)


Advisors’ Opinion:

  • [By Garrett Cook]

    Lastly, Citi says Marathon Petroleum (NYSE: MPC) and MPLX LP (NYSE: MPLX) remain Buy rated the heels of benefits derived from strong product demand and the NGL recovery.

  • [By Ben Levisohn]

    JPMorgan analyst Phil Gresh and team explain what they got wrong about Marathon Petroleum (MPC), as they cut its rating to Neutral from Overweight following yesterday’s disastrous financial results from MPLX (MPLX):

stock options: Terex Corporation(TEX)


Advisors’ Opinion:

  • [By Reuben Gregg Brewer]

    Ever walk past a construction site? It’s hard not to be enthralled by all the heavy construction machinery moving things around. With the world’s developing economies still building at a relatively fast pace and developing economies, like the United States, in desperate need of upgrading their aging infrastructure, the companies behind that construction machinery could be just as exciting as a construction site in the years ahead. Which is why Caterpillar Inc. (NYSE:CAT), Cummins Inc. (NYSE:CMI), and Terex Corporation (NYSE:TEX) are three of the top construction machinery stocks to look at right now.

  • [By Ben Levisohn]

    Yesterday, Terex (TEX) announced that it would sell its ports business to Konecranes for $1.3 billion. Today, Baird’s Mircea Dobre and Joseph Grabowski upgraded Terex to Outperform from Neutral, arguing that the sale makes a takeover by China’s Zoomlion that much easier. They explain:

    Balint Porneczi/Bloomberg News

    The sale of MHPS to Konecranes is a positive catalyst on multiple fronts: shareholders got an attractive multiple for what historically has been a challenged business with further upside possible given 25% equity ownership in Konecranes, execution risk is diminished as new CEO can focus on operational improvement without the effort required to integrate the Terex and Konecranes businesses, and finally, the MHPS sale makes it easier for Zoomlion to acquire remaining Terex.


    While our upgrade is not reliant on Zoomlion acquiring Terex, the MHPS transaction could make a firm Zoomlion offer more likely.

    At the margin, a Zoomlion deal appears easier to get done: 1) the remaining businesses fit better with Zoomlions existing product portfolio of construction equipment, cranes, and various commercial and municipal equipment, 2) given the attractive terms of the MHPS sale, the funding hurdle required to acquire Terex is lowered, 3) many of the CFIUS issues center around national security concerns regarding the nations ports, no longer a concern given MHPS sale.


    Dobre and Grabowski also raised their price target on Terex to $30, up from $24. With Terex off 0.1% at $24.88 today, that leaves 21% upside in the stock to Baird’s target.

    In February, I wrote about Chinese demand for U.S. companies, including Terex.

  • [By Ben Levisohn]

    RBC’sSeth Weber and team offer their thoughts on Zoomlion’s revised bid for Terex (TEX):

    Bloomberg News

    After the close today, Terex announced that it is moving forward in its negotiations with Zoomlion Heavy Industry Science and Technology Co. following receipt of a non-binding proposal from the Chinese company to acquire all outstanding shares for $31/share in cash.

  • [By Ben Levisohn]

    Third and a trigger for the change: China becomes an active bidder in the space. Chinas Zoomlion bid for Terex (TEX) ($3.3B) along with Haier/General Electric (GE) ($5.4B) and several ChemChina proposed deals in industrials changes the upside/downside skew, particularly on lower quality/more challenged names. The Terex bid does not appear to be one-off. Chinese outbound M&A announcements rose to record highs in 15; to $112B (up 57% from 2014) in total acquisitions. Industrials formed a large and rising portion, at ~12B completed. Thats roughly equal to the 3 prior years industrials deals combined, and is the highest on record. Energy and materials accounted for ~15% of 15 spend vs. ~83% in 2011. Even lower quality or more currently challenged machinery franchises have distribution which could be highly attractive to new entrants…

  • [By Ben Levisohn]

    Shares of Terex (TEX) had surged 32% as of the close of trading last Thursday–but dropped 14% the next day after China’s Zoomlion announced that it wouldn’t be pursuing a purchase of the U.S. crane maker after all. In the aftermath of the scuttled deal, Morgan Stanley’s Mili Pothiwala and Nigel Coe cut Terex to Equal Weight from Overweight:

    Balint Porneczi/Bloomberg News

    On Friday morning, Zoomlion announced it had terminated its bid for its proposed acquisition of Terex for $31/ share. This was a clear negative for Terex shares, which traded down ~15% on Friday to $20, given the absence of an event-driven catalyst (following the sale of MHPS to Konecranes, which we assume will be completed). However, we think that the stock’s current discount to the Machinery group on a P/E basis (20%+) is justified, given a still challenged underlying operating environment for the RemainCo, as well as historically uneven company execution – both of which return to the forefront of the investment debate following the removal of the M&A bull case.

    To which all we can say is: Oops.

    Shares of Terex have dropped 0.5% to $20.78

     

Leave a Reply

Your email address will not be published. Required fields are marked *